Citation Impact
Citing Papers
Designed protein logic to target cells with precise combinations of surface antigens
2020 StandoutScienceNobel
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer
2010
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
2010 Standout
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23
2016
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
2015 StandoutNobel
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
2016
De novo design of immunoglobulin-like domains
2022 StandoutNobel
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
Image-Guided Oncologic Surgery Using Invisible Light: Completed Pre-Clinical Development for Sentinel Lymph Node Mapping
2006 StandoutNobel
Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
2007
Natural products: A continuing source of novel drug leads
2013 Standout
The cytochrome P450 4 (CYP4) family
1997
An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate‐specific membrane antigen small molecule derivatives
2006
Prodrug Strategies in Anticancer Chemotherapy
2007
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Linker Technologies for Antibody–Drug Conjugates
2013
Cancer Statistics, 2006
2006 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
2012
The safety and side effects of monoclonal antibodies
2010
Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer
2016 Standout
The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
2008
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
1990 StandoutNature
Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies
2013
Potent antibody drug conjugates for cancer therapy
2009
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Antibody therapy of cancer
2012 Standout
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Biochemical Mechanisms of Induction of Hepatic Peroxisome Proliferation
1989
Evidence for Transcriptional Induction of the Liver Fatty-Acid-Binding-Protein Gene by Bezafibrate in the Small Intestine
1995
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
1996
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
2016
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
2015 Standout
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
2001 Standout
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
Cancer‐Cell‐Phenotype‐Dependent Differential Intracellular Trafficking of Unconjugated Quantum Dots
2008
Natural products to drugs: natural product derived compounds in clinical trials
2005
Hepatic peroxisome proliferation in rodents and its significance for humans
1993
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Natural products in drug discovery
2008 Standout
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
2012
Enantioselectivity in the induction of peroxisome proliferation by 2‐ethylhexanoic acid
1992
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Arming antibodies: prospects and challenges for immunoconjugates
2005
Update on tubulin-binding agents
2005
An analysis of the attrition of drug candidates from four major pharmaceutical companies
2015 Standout
Renal clearance of quantum dots
2007 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen
2005
Targeting Tumor Vasculature with Aptamer-Functionalized Doxorubicin–Polylactide Nanoconjugates for Enhanced Cancer Therapy
2015
The emerging role of computational design in peptide macrocycle drug discovery
2020
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Azole-Based Energetic Salts
2011 Standout
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Safety of biologics, lessons learnt from TGN1412
2009
Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1
2015
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Improving the Odds of Success in Drug Discovery: Choosing the Best Compounds for in Vivo Toxicology Studies
2013
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
2019
Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody
2015
Drugs in the tetrazole series. (Review)
2007
Computational design of mixed chirality peptide macrocycles with internal symmetry
2020 StandoutNobel
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation
1995
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Chimeric Antigen Receptor Therapy
2018 Standout
Evidence for Transcriptional Induction of the Liver Fatty‐Acid‐Binding‐Protein Gene by Bezafibrate in the Small Intestine
1995
The PPARs: From Orphan Receptors to Drug Discovery
2000 Standout
Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
2006
Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties
2006
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Engineering Cytochrome P450 BM3 for Terminal Alkane Hydroxylation
2006 StandoutNobel
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
1999 Standout
The Traditional Medicine and Modern Medicine from Natural Products
2016 Standout
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Works of Mark Milton being referenced
A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer
2004
PhRMA White Paper on ADME Pharmacogenomics
2008
Lack of evidence for a hepatic peroxisome proliferator receptor and an explanation for the binding of hypolipidaemic drugs to liver homogenates
1988
Evaluation of Drug-Transporter Interactions Using In Vitro and In Vivo Models
2007
On the mechanism of induction of microsomal cytochrome P450IVA1 and peroxisome proliferation in rat liver by clofibrate
1990
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies
2009
Disposition and Pharmacokinetics of L-N6-(1-Iminoethyl)Lysine-5-Tetrazole-Amide, a Selective iNOS Inhibitor, in Rats
2004
The determination and interpretation of the therapeutic index in drug development
2012
The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?
2009
The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development
2009